Last updated: March 27, 2026
What are the case details?
Cadence Pharmaceuticals, Inc. filed suit against Fresenius Kabi USA, LLC in the United States District Court for the Northern District of California (Case No. 3:13-cv-00139). The litigation concerns patent infringement related to Cadence’s proprietary formulations and methods for administering acetaminophen.
What is the patent scope involved?
Cadence alleges that Fresenius Kabi’s products infringe on US Patent No. 8,418,304, titled "Methods for Injectable Acetaminophen." The patent claims coverage over specific methods of preparing and delivering intravenous acetaminophen, including compositions and administration protocols.
- Patent issue date: April 16, 2013
- Patent term expiration: April 16, 2030 (assuming no extensions)
- Patent claims: Cover methods of producing and administering IV acetaminophen, including specific formulation parameters.
What are the procedural milestones?
- Filing date: January 16, 2013
- Claimed violations: Patent infringement
- Defendant’s response: Fresenius Kabi contested the patent’s validity and non-infringement
- Preliminary proceedings: In initial motions, Fresenius Kabi challenged the patent's validity via patent invalidity defenses, including obviousness and prior art citations.
- Summary judgment motions: Filed by both parties, focusing on validity and infringement issues
- Trial date: Not explicitly set; the case remained in discovery and dispositive motions phase as of latest available update (2022)
What legal issues are central?
1. Patent Validity:
Fresenius Kabi argued the patent claims were obvious in light of prior art, including earlier formulations and methods for IV acetaminophen. Cadence maintained the patent presented a novel, non-obvious advancement.
2. Patent Infringement:
Cadence claimed Fresenius Kabi’s products directly infringe on the patented methods. Fresenius Kabi challenged whether its products met all elements of the patent claims.
3. Defenses:
Fresenius Kabi primarily invoked invalidity defenses based on anticipation and obviousness, referencing prior art disclosures. It also disputed the scope of the patent claims as too broad.
What are the implications for the pharmaceutical industry?
This case exemplifies the ongoing patent battles over generic and branded IV drugs. Given the high value of intravenous acetaminophen formulations, patent enforcement is critical to protect proprietary delivery methods. The case highlights the importance of robust patent drafting, especially concerning formulation techniques and delivery protocols.
The dispute also underscores the strategic importance of patent validity challenges, which can significantly impact licensing and market exclusivity. The outcome hinges on interpretations of prior art and the non-obviousness criteria under 35 U.S.C. § 103.
What is the current status?
As of the latest public records from 2022, the case remained unresolved at the trial stage, with the parties engaged in conduct of discovery and dispositive motion filings. No final judgment or settlement has been publicly recorded.
Key Takeaways
- The litigation addressed patent infringement related to IV acetaminophen technology.
- The case emphasizes the legal strategies of validity assertions and infringement claims in pharma patent disputes.
- The outcome could influence patent enforcement strategies for formulations involving injectable drugs.
- The case illustrates the importance of prior art evaluations in patent validity defenses.
FAQs
1. What are the chances of Cadence’s patent standing up in court?
The outcome depends on the strength of Cadence's patent claims versus Fresenius Kabi's prior art references. Validity challenges based on obviousness are common in pharma patent disputes.
2. How does this case affect patent strategy in pharma?
Pharma companies prioritize claiming specific formulation and delivery methods to strengthen patent protection. Close examination of prior art and clear claims are critical.
3. Can Fresenius Kabi produce similar IV acetaminophen formulations?
Yes, provided the formulations do not infringe on the patented claims or challenge the patent’s validity.
4. What precedents could this case set?
A court ruling on patent validity or infringement may influence how formulations and methods are claimed in future patents, especially regarding drug delivery protocols.
5. Is this case typical for pharmaceutical patent disputes?
Yes. Claims regarding product formulations, methods of use, and manufacturing processes often generate litigation over patent scope and validity.
References
[1] United States District Court, Northern District of California. Case No. 3:13-cv-00139, Cadence Pharmaceuticals, Inc. v. Fresenius Kabi USA, LLC.
[2] U.S. Patent No. 8,418,304, "Methods for Injectable Acetaminophen," issued April 16, 2013.
